Suppr超能文献

多巴胺、肾上腺素和输血治疗严重急性营养不良或严重消瘦伴霍乱或其他致脱水腹泻儿童液体难治性休克的疗效:一项随机对照临床试验方案。

Efficacy of dopamine, epinephrine and blood transfusion for treatment of fluid refractory shock in children with severe acute malnutrition or severe underweight and cholera or other dehydrating diarrhoeas: protocol for a randomised controlled clinical trial.

机构信息

Nutrition and Clinical Services Division, International Centre for Diarrhoeal Disease Research,Bangladesh (icddr,b), Dhaka, Bangladesh.

Department of Cardiology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.

出版信息

BMJ Open. 2023 Apr 12;13(4):e068660. doi: 10.1136/bmjopen-2022-068660.

Abstract

INTRODUCTION

Diarrhoea is one of the leading causes of under-5 childhood mortality and accounts for 8% of 5.4 million global under-5 deaths. In severely malnourished children, diarrhoea progresses to shock, where the risk of mortality is even higher. At icddr,b Dhaka Hospital, the fatality rate is as high as 69% in children with severe malnutrition and fluid refractory septic shock. To date, no study has evaluated systematically the effects of inotrope or vasopressor or blood transfusion in children with dehydrating diarrhoea (eg, in cholera) and severe acute malnutrition (SAM) or severe underweight who are in shock and unresponsive to WHO-recommended fluid therapy. To reduce the mortality of severely malnourished children presenting with diarrhoea and fluid refractory shock, we aim to compare the efficacy of blood transfusion, dopamine and epinephrine in fluid refractory shock in children who do not respond to WHO-recommended fluid resuscitation.

METHODS AND ANALYSIS

In this randomised, three-arm, controlled, non-masked clinical trial in children 1-59 months old with SAM or severe underweight and fluid refractory shock, we will compare the efficacy of dopamine or epinephrine administration versus blood transfusion in children who failed to respond to WHO-recommended fluid resuscitation. The primary outcome variable is the case fatality rate. The effect of the intervention will be assessed by performing an intention-to-treat analysis. Recruitment and data collection began in July 2021 and are now ongoing. Results are expected by May 2023.

ETHICS AND DISSEMINATION

This study has been approved by the icddr,b Institutional Review Board. We adhere to the 'Declaration of Helsinki' (2000), guidelines for Good Clinical Practice. Before enrolment, we collect signed informed consent from the parents or caregivers of the children. We will publish the results in a peer-reviewed journal and will arrange a dissemination seminar.

TRIAL REGISTRATION NUMBER

NCT04750070.

摘要

引言

腹泻是导致 5 岁以下儿童死亡的主要原因之一,占全球 540 万 5 岁以下儿童死亡人数的 8%。在严重营养不良的儿童中,腹泻会发展为休克,死亡率更高。在 icddr,b 达卡医院,严重营养不良且对液体无反应的感染性休克儿童的死亡率高达 69%。迄今为止,尚无研究系统评估在脱水性腹泻(如霍乱)和严重急性营养不良(SAM)或严重消瘦且对世卫组织推荐的液体疗法无反应的休克儿童中使用儿茶酚胺或血管加压素或输血的效果。为降低腹泻和液体无反应性休克的严重营养不良儿童的死亡率,我们旨在比较输血、多巴胺和肾上腺素在对世卫组织推荐的液体复苏无反应的儿童中治疗液体无反应性休克的疗效。

方法和分析

在这项针对 1-59 个月大的 SAM 或严重消瘦且液体无反应性休克儿童的随机、三臂、对照、非盲临床试验中,我们将比较对世卫组织推荐的液体复苏无反应的儿童使用多巴胺或肾上腺素与输血的疗效。主要结局变量是病死率。将通过意向治疗分析评估干预效果。招募和数据收集于 2021 年 7 月开始,目前正在进行。结果预计于 2023 年 5 月公布。

伦理和传播

这项研究已获得 icddr,b 机构审查委员会的批准。我们遵守“赫尔辛基宣言”(2000 年)和良好临床实践指南。在入组前,我们会从儿童的父母或监护人那里收集签署的知情同意书。我们将在同行评议的期刊上发表研究结果,并安排传播研讨会。

试验注册号

NCT04750070。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec2e/10106066/92d9f195f864/bmjopen-2022-068660f01.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验